A Multiple-Dose Pharmacokinetics Study of Three Gefapixant (AF-219/MK-7264) Formulations

NCT02790840 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: Omeprazole
DRUG: Omeprazole
DRUG: Gefapixant
DRUG: Gefapixant

Sponsor

Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)